Company profile
HST Global, Inc.
OTC: HSTC · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ 38GM —SS 48
v0.1 · 25/100 weight · pillars only
↑ Altman-Z, listing tenure · ↓ workforce scale, balance-sheet leverage
Methodology →Revenue TTM
$767.9k
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$146.2k
Employees
1
as of 2026-08-20
Market cap
$91.9M
as of 2026-08-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02023
Net income-$146.2k-$146.2k2023
Operating income-$140.9k-$140.9k2023
Total assets$1.5k$1.5k2023
Liabilities$593.6k$593.6k2023
Equity-$592.1k-$592.1k2023
Revenue trend
FY2018 – FY2023 · USD
FY18
FY18
FY19
FY20
FY21
FY22
FY23
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is HST Global, Inc.’s revenue?
HST Global, Inc. booked $0 in FY2023 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Fractyl Health, Inc.28DParabilis Medicines, Inc.——Revium Recovery Inc.——MAIA Biotechnology, Inc.34DvTv Therapeutics Inc.57CAnnovis Bio, Inc.32DKey facts
CEOMichael Fortkort
SectorHealthcare
IndustryBiotechnology
HeadquartersHampton, VA
ExchangeOTC: HSTC
Employees1
IPO date2002-06-24
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.